Clinically, the differentiation between ischemic (ICM) and non-ischemic (NICM) human cardiomyopathies is highly relevant, as ICM and NICM differ with respect to prognosis and certain aspects of pharmacological therapy, despite a common final phenotype characterized by ventricular dilatation and reduced contractility. So far, it is unclear whether microarray-based signatures can be used to infer the etiology of heart failure. Using three different classification algorithms, we independently analyzed one cDNA-and two publicly available high-density oligonucleotide microarray studies comprising a total of 279 endstage human heart failure samples. When classifiers identified in a single study where applied to the remaining studies, misclassification rates >25% for ICM and NICM specimens were noted, indicating poor separation of both etiologies.
Introduction
Heart failure due to dilated cardiomyopathy, characterized by impaired contractile function of one or both ventricles and dilatation of the cardiac chambers, is a leading cause of hospitalization and death in Western countries (14) . Most frequently, it develops in the setting of coronary atherosclerosis, with ischemic cardiomyopathy (ICM) accounting for more than 50% of cases of heart failure (2). The second largest heart failure entity are dilated cardiomyopathies of non-ischemic origin (NICM), comprising various subgroups such as valvular and hypertensive heart disease, viral myocarditis, hereditary cases, toxic forms (e.g. alcohol and anthracycline cardiomyopathy), as well as a subset of idiopathic cases where no specific cause can be determined.
In general, pharmacological treatment of overt heart failure is largely based on functional New York Heart Association (NYHA) status and differs little with respect to the underlying disease etiology. However, it has become increasingly clear that long-term prognosis and the response to certain pharmacologic modalities may very well differ between ICM and NICM. For instance, response to digoxin and amiodarone was found to be better in nonischemic patients (1, 30) . Likewise, large epidemiological studies have shown that heart failure of ischemic origin is associated with a worse outcome compared to NICM (2, 18) . Therefore, the differentiation between ischemic and nonischemic cases is clinically highly relevant, but relies, so far, mainly on the results of a coronary angiography. While this invasive technique will correctly confirm (or rule out) significant coronary atherosclerosis in most cases, it might be misleading in up to 20% of patients who present after a myocardial infarction with Page 4 of 39 -Genomics of Human Cardiomyopathies -5 spontaneous recanalization of the culprit coronary artery. Therefore, these patients will be misclassified as "non-ischemic" in the absence of additional significant coronary stenoses (40). In this respect, genomic studies hold great promise to improve our current classification schemes. While we have recently reported a common and robust gene expression profile characteristic of failing human ventricular myocardium across >100 NICM and non-failing (NF) samples of four independent microarray studies (4), it is currently less clear whether microarray-based signatures can also be used to infer the etiology of heart failure in end-stage NICM and ICM. Several pilot studies have suggested differences in genomic signatures between different etiologies of heart failure (7, 21, 22, 33), while others have failed to clearly differentiate between ischemic and idiopathic dilated cardiomyopathy based on transcript profiling (12, 31). Therefore, we performed class prediction analysis independently in one cDNA-and two publicly available high-density oligonucleotide microarray studies, comprising a total of 279 human myocardial samples. We then applied potential classifiers identified in a single study to the remaining datasets to test whether etiology-specific patterns of gene expression are discernible in end-stage human heart disease of ischemic and non-ischemic origin.
Material and Methods

cDNA microarray study
We performed a genome-wide expression study which comprised septal myocardial samples from heart failure patients with end-stage NICM (n=16) and ICM (n=10). While the latter patients had either a severe two or three vessel coronary disease ( 75% stenosis) and/or a history of myocardial infarction, coronary angiography showed no signs of significant (>50%) stenoses in NICM subjects. Detailed patient characteristics are given in Supplemental Table 1 Designed as a two-color microarray experiment, each NICM and ICM sample was labeled with Cy3 and hybridized against a common pool of RNA from 15 non-failing hearts labeled with Cy5. RNA amplification, labeling and hybridization to RZPD Unigene 3.1 cDNA microarrays (37.5K) were carried out as described previously (4) . Pre-processing and most of the statistical analysis were done using Bioconductor (www.bioconductor.org). The cDNA microarray raw data were normalized using the "variance stabilization" method (VSN (20)) and the arrayMagic software package (10). Hierarchical clustering of genes and samples was based on the Euclidean distance measure. The platform iCHIP (Integration Centre of HIgh throughPut experiments; www.ichip.de) was used to export the microarray data via MAGE-ML to the repository ArrayExpress of the European Bioinformatics Institute (http://www.ebi.ac.uk/arrayexpress, accession number E-CVDE-1).
Etiological classification of three microarray studies of human heart failure
We classified NICM and ICM samples in one own cDNA (E-CVDE-1) and two publicly available high-density oligonucleotide microarray studies (NCBI Gene Expression Omnibus database accession numbers GSE5406 and GSE1145). Dataset GSE5406 represents the largest microarray study of human heart failure so far, comparing 108 ICM and 86 NICM samples hybridized to Affymetrix HG-U133A arrays (19). Dataset GSE1145 consists of 32 ICM and 27 NICM samples hybridized to Affymetrix HG-U133 2.0 plus arrays (www.cardiogenomics.org). In summary, the current meta-analysis comprised a total of 150 ICM and 129 NICM samples from three independent microarray studies. More detailed information regarding these studies is provided in Table 1 .
Affymetrix probes and cDNA clones were merged between different microarray platforms using Bioconductor annotation packages (www.bioconductor.org). 
Results
Classification of non-ischemic and ischemic cardiomyopathies
Applying three different classification algorithms to our own cDNA microarray dataset (E-CVDE-1) and two larger, publicly available microarray datasets (GSE1145 and GSE5406), we found that on average one fourth of the samples were misclassified (range 14% -32%; Figure 1 and Supplemental with Random Forest (14%) and Penalized Logistic Regression (17%) in dataset GSE1145. This is best exemplified for the PLR method in GSE1145 (Supplemental Figure 2) , where one can appreciate a high variation even for those samples that were correctly classified. The variability suggests that the classifier itself is not very robust. This is supported by the fact that the results of the best classifier (correct classification of 86% of samples with Random Forest in dataset GSE1145) could not be reproduced in independent datasets, as misclassification rates were 34% and 35% in datasets GSE5406 and E-CVDE-1, respectively. As a limitation of the analysis of different microarray platforms, the 509 non-redundant classifier genes could only be matched to a subset of identifiers in the two other datasets (GSE5406: 414 genes and E-CVDE-1: 289 genes). To exclude that the poor classification result in datasets GSE5406 and ECVDE-1 might be due to the lack of genes important for the classification process in these datasets, we applied the Random Forest algorithm in GSE1145 using 414 genes available in GSE5406 and 289 genes available in dataset ECVDE-1. Due to overfitting, these results can not be compared to the initial classification result for the data set. Therefore, we also performed the Random Forest classification based on the 509 non-redundant classifier genes. There was no difference between the three resulting misclassification rates (data not shown). This suggests that the poor classification results obtained with the RF classifier from GSE1145 in datasets GSE5406 and E-CVDE-1 is not due to the lack of genes important for the classification algorithm. To further support this notion, we performed an additional analysis in the two largest datasets GSE1145 and GSE5406, encompassing >90% of all 279 samples included in the present manuscript: Based on ENTREZ IDs, we first determined the genes common to both datasets. Second, we applied the Random Forest classification procedure in GSE1145 using only probe sets that were shared between both datasets.
Supplemental Figure 5 shows that the classification results obtained in dataset GSE1145 (misclassification rate 14%) are similar to our previous analysis using the complete dataset ( Figure 1 ). However, application of this classifier to GSE5406 still yielded a poor classification with a misclassification rate of 34%.
Likewise, we found no clear evidence that gender influences the misclassification rates for NICM or ICM samples (8). Even though men are in general overrepresented in both etiologies (across all studies ~60% and ~85% of subjects were male in the NICM and ICM groups, respectively), sex did not play a major role for the results of the current classification for NICM or ICM samples (Supplementary Table 1 ). This was also supported by a separate analysis of myocardial samples of male patients only which yielded similar results compared to analysis of the entire dataset (Supplemental Figure 6) In an additional classification analysis, we examined whether a published 90-gene classifier for ICM and NICM (22) can correctly distinguish ischemic from non-ischemic cardiomyopathies in the three aforementioned microarray datasets.
Here, the classifier genes were only reduced in dataset E-CVDE-1 (35 genes).
However, 40% of 279 myocardial samples were misclassified again, indicating that results from this study cannot be extrapolated to independent cardiomyopathy datasets ( Figure 1 ).
In contrast, by applying our previously described genomic classifier for heart failure (4) to the largest dataset (GSE5406, Supplemental Figure 4) , we now achieved successful classification between non-failing and failing myocardium in a total of 347 of 360 samples, yielding an overall prediction accuracy of 96.4% which is in sharp contrast to the high misclassification rate between NICM and ICM in the same microarray dataset.
Distinct biological processes in ischemic and non-ischemic dilated cardiomyopathies
In order to obtain etiology-specific transcriptional patterns in NICM vs.
ICM, we performed Gene Ontology and KEGG pathway analysis with classifiers derived from each dataset separately. Furthermore, to define a common, minimal denominator across independent datasets, we also performed a GO analysis with 458 classifier genes that were concordantly deregulated in at least two of the three microarray studies (Figure 2 A and Supplemental Tables 2 and 3) . As a result, we found an overrepresentation of cytoskeletal transcripts, genes encoding for the major histocompatibility complex, and antigen processing and presentation pathways in NICM samples. In contrast, the Gene Ontology groups of "inflammatory response", "cytokine activity", and "G-protein-coupled receptor binding" were enriched in ICM samples (Figure 2 resulted only in a list of 13 genes in the largest dataset (GSE5406) with negligible overlap to the other microarray datasets (data not shown).
Discussion
Classifying end-stage ischemic and non-ischemic cardiomyopathies
Clinically, the differentiation into non-ischemic and ischemic cardiomyopathies is highly relevant as, in non-ischemic cases, secondary causes (e.g. myocarditis and excessive alcohol consumption) need to be identified, while ischemic patients, on the contrary, may benefit from revascularization and secondary preventive pharmacotherapy with lipid lowering drugs and anti-platelet agents. However, correct classification between ischemic and non-ischemic cases is difficult, as highlighted by a study using gadolinium enhanced cardiovascular magnetic resonance imaging which suggested an incorrect assignment of ischemic and non-ischemic heart failure etiology in 13% of heart failure patients (24). Likewise, the Assessment of Treatment with Lisinopril and Survival study (ATLAS) showed an incorrect classification of NICM and ICM cases in up to 28% based on autopsy data (36). In this respect, incorrect assignment of disease etiology based on coronary angiography would not only be misleading in patients in whom spontaneous revascularization of the coronary artery occurs after a myocardial infarction (40), but also in patients who are classified as NICM and who show major coronary findings at autopsy (36).
By convention, new diagnostic tests should be validated against an established gold standard. As several clinical modalities including coronary angiography and MRI have been shown to lack the sensitivity to correctly classify the etiology of heart failure in all cases, the most appropriate reference standard is post-mortem autopsy. As a limitation, autopsy data was only available for a subset of cases in our own cDNA microarray study (Supplemental Table 1 ) and has not been provided in any of the published studies dealing with different etiologies of heart failure (19, 22). Thus, in the present study, phenotypic classification was largely based on information routinely used by clinicians to assign patients to ischemic or non-ischemic disease etiologies. However, it is of interest to note that even in those cases that could be diagnosed unequivocally as ICM, misclassification based on microarray data was common. As an example, five out of ten ICM samples were misclassified in the cDNA microarray study -despite the fact that these patients had a history of prior myocardial infarctions, coronary artery bypass graft surgeries and three-vessel-coronary disease on coronary angiograms. Several explanations are possible. First, a severe ICM is expected to exhibit significant heterogeneity at the molecular level, reflecting areas of non-ischemic, ischemic, stunned or hibernating myocardium, all of which show distinct genomic profiles in animal models and human heart failure (15-17). In agreement with this hypothesis, we noted significant heterogeneity of ischemia marker genes in samples from ICM patients (Figure 3 ).
The fact that those ischemia marker genes were also up-regulated in some NICM samples goes along with the fact that coronary microvascular dysfunction has been shown to be prevalent in NICM as well (26), leading to defined areas of ischemia which might show a gene expression profile similar to ICM. Recent magnetic resonance imaging studies, showing patchy or longitudinal striae of midwall enhancement with a different distribution pattern to the fibrotic areas observed in coronary artery disease, support this hypothesis (24). Second, it might be possible that the underlying etiology is blurred in endstage human heart failure in a substantial number of cases. After an initial cardiac insult, producing a decline in pump function, myocardial remodeling and dilatation in ischemic as well as non-ischemic heart failure is aggravated by systemic activation of neurohormonal systems. Hence, the concept of the final common pathway of cardiomyopathic diseases has been established, where dilatation is a non-specific phenotype of severely stressed myocardium, irrespective of the initiating cardiac insult (23). In line with this notion, all major pharmacological interventions known to increase survival in heart failure patients (NICM and ICM) aim at disrupting the vicious circle of neurohormonal dysregulation, i.e. they inhibit either the adrenergic or the renin-angiotensinaldosteron system. Thus, expression patterns in end-stage human heart disease might be dominated by common heart failure pathways, as demonstrated by our previously described genomic classifier for heart failure which was derived from NICM vs. NF tissue samples, but discriminated ICM from NF myocardium as well (4) (Supplementary Figure 4) .
As a limitation, we did not attempt to stratify the NICM cases for post myocarditis, end-stage hypertensive cardiomyopathy, alcohol-induced or familial forms of NICM. We felt that the clinical information provided was insufficient even for our own patients, with the large majority being classified as "idiopathic" NICM.
Future studies are necessary to separate those entities, preferably at earlier disease stages by examining endomyocardial biopsies.
From a methodological point of view, integrating independent datasets into a common analysis remains a challenge, even though some strategies have been proposed (32, 37). Cross-platform analysis of cancer microarray data may improve gene expression based classification of phenotypes (32, 37). However, it remains questionable if the gain of information obtained from examining a larger number of samples can compensate for the loss of information resulting from data reduction. In the present study, we avoided the loss of information and used our own as well as publicly-available data sets to validate our results. Of note, this approach was successfully applied in previous studies (4, 29) . However, for ICM and NICM, we were neither able to identify a novel robust classifier in three independent datasets nor to apply a published classifier from a fourth study (22).
Our additional analysis, where only common genes of independent datasets were used for classification, argues against a technical limitation for the poor misclassification rate. In summary, we presented multiple lines of evidence for a poor separation of ICM and NICM etiologies based on independent microarray studies and different classification methods.
Distinct biological processes in ischemic and non-ischemic dilated cardiomyopathies
Atherosclerosis is currently considered to be an inflammatory disease in which the initiation and progression of an atherosclerotic towards an unstable plaque is driven by leukocyte recruitment mediated by various inflammatory mediators, including chemotactic cytokines or chemokines (11). Consistent with this hypothesis, ICM samples were characterized by the functional Gene Ontology classes of "inflammatory response", "chemotaxis", "cytokine activity", and "myeloid cell differentiation" (Figure 2 ). Ingenuity pathway analysis suggested a gene-gene interaction network centered around the immediate early response genes FOS and JUNB. It has been shown that brief episodes of myocardial ischemia activate a distinct genetic program promoting cardioprotection and cell survival with the immediate early response genes being amongst the most consistent findings of ischemic preconditioning (15, 27).
In NICM, GO analysis suggested involvement of immune processes with up-regulation of major histocompatibility complex genes. In line with this finding, KEGG pathway analysis revealed "antigen processing and presenting pathways" to be more prominent in NICM than ICM. Of note, idiopathic non-ischemic dilated cardiomyopathy has been proposed as a disease with autoimmune features (25).
The finding that immune processes were involved in both ICM and NICM is consistent with our previous study where we found a deregulation of the immune system to be characteristic of end-stage human failing myocardium (4) . In addition to deregulation of immune processes in NICM, it is of particular interest to find deregulation of cytoskeletal and sarcomere transcripts as well (Supplemental Tables 2 and 3 ), especially as a wide variety of studies point to a link between mutations in cytoskeletal genes and the initiation of dilated cardiomyopathy (13). However, one has to keep in mind that our classification results and the low number of differentially expressed genes suggest substantial similarities in the transcriptomic response of ischemic and non-ischemic cardiomyopathies. Transcriptional differences between the two etiologies do exist, but these differences seem to be rather small when the analysis is based on the pre-assigned clinical categories. Thus, prospective studies are required to identify specific subgroups of patients and test whether distinct transcriptomic patterns and related biological processes carry a different prognosis and require individualized therapies (i.e. platelet inhibition for NICM patients with an ischemic gene expression profile).
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